Eric Wang

7486842, Feb 3, 2009

Sep 17, 2007

11/856541

Massimiliano Gasparri - Los Angeles CA, US
Keren O. Perlmutter - Pacific Palisades CA, US
Sharon M. Perlmutter - Pacific Palisades CA, US
Eric Wang - Tustin CA, US
Paul R. Klamer - La Canada CA, US
Christopher J. Cookson - Studio City CA, US

Warner Bros. Entertainment Inc. - Burbank CA
AOL LLC - Dulles VA

G06K 9/32

382294, 382282, 382284, 358538, 358540, 358450

Separations or images relating to film or other fields may be registered using a variety of features, such as, for example: (1) correcting one or more film distortions; (2) automatically determining a transformation to reduce a film distortion; (3) applying multiple criteria of merit to a set of features to determine a set of features to use in determining a transformation; (4) determining transformations for areas in an image or a separation in a radial order; (5) comparing areas in images or separations by weighting feature pixels differently than non-feature pixels; (6) determining distortion values for transformations by applying a partial distortion measure and/or using a spiral search configuration; (7) determining transformations by using different sets of features to determine corresponding transformation parameters in an iterative manner; and (8) applying a feathering technique to neighboring areas within an image or separation.

7672541, Mar 2, 2010

Oct 30, 2007

11/929191

Massimiliano Gasparri - Los Angeles CA, US
Keren O. Perlmutter - Pacific Palisades CA, US
Sharon M. Perlmutter - Pacific Palisades CA, US
Eric Wang - Tustin CA, US
Paul R. Klamer - La Canada CA, US
Christopher J. Cookson - Studio City CA, US

Warner Bros. Entertainment Inc. - Burbank CA
AOL LLC - Dulles VA

G06K 9/32

382294, 382169, 382275, 382284, 358 326, 358 327

Separations or images relating to film or other fields may be registered using a variety of features, such as, for example: (1) correcting one or more film distortions; (2) automatically determining a transformation to reduce a film distortion; (3) applying multiple criteria of merit to a set of features to determine a set of features to use in determining a transformation; (4) determining transformations for areas in an image or a separation in, a radial order; (5) comparing areas in images or separations by weighting feature pixels differently than non-feature pixels; (6) determining, distortion values for transformations by applying a partial distortion measure and/or using a spiral search configuration; (7) determining transformations by using different sets of features to determine corresponding transformation parameters in an iterative manner; and (8) applying a feathering technique to neighboring areas within an image or separation.

8318132, Nov 27, 2012

Feb 17, 2009

12/372717

Hartmuth C. Kolb - Playa Del Rey CA, US
Joseph C. Walsh - Pacific Palisades CA, US
Wei Zhang - Los Angeles CA, US
Peter J. H. Scott - Marina-del-Rey CA, US
Kai Chen - Los Angeles CA, US
Vani P. Mocharla - Los Angeles CA, US
Dhanalakshmi Kasi - Los Angeles CA, US
Gang Chen - Los Angeles CA, US
Eric Wang - San Diego CA, US
Anjana Sinha - San Diego CA, US

Siemens Medical Solutions USA, Inc. - Malvern PA

A61K 51/00
A61M 36/14

424 111, 424 189, 424 185, 424 181, 424 165, 424 91

Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled flavones, coumarins, carbazoles, quinolinones, chromenones, imidazoles and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease.

8420052, Apr 16, 2013

Jul 24, 2009

12/509259

Hartmuth C. Kolb - Playa Del Rey CA, US
Joseph C. Walsh - Pacific Palisades CA, US
Wei Zhang - Los Angeles CA, US
Umesh B. Gangadharmath - Los Angeles CA, US
Dhanalakshmi Kasi - Los Angeles CA, US
Kai Chen - Rockville MD, US
Anjana Sinha - San Diego CA, US
Eric Wang - San Diego CA, US
Gang Chen - Los Angeles CA, US
Peter J. H. Scott - Ypsilanti MI, US
Henry Clifton Padgett - Hermosa Beach CA, US
Qianwa Liang - Hacienda Heights CA, US
Zhiyong Gao - Wynnewood PA, US
Tieming Zhao - Los Angeles CA, US
Chunfang Xia - Los Angeles CA, US
Vani P. Mocharla - Los Angeles CA, US

Siemens Medical Solutions USA, Inc. - Malvern PA

A61K 51/00
A61M 36/14

424 189, 424 111, 424 165, 424 181, 424 185

Provided herein are compounds and compositions which comprise the formulae as disclosed herein, wherein the compound is an amyloid binding compound. An amyloid binding compound according to the invention may be administered to a patient in amounts suitable for in vivo imaging of amyloid deposits, and distinguish between neurological tissue with amyloid deposits and normal neurological tissue. Amyloid probes of the invention may be used to detect and quantitate amyloid deposits in diseases including, for example, Down's syndrome, familial Alzheimer's Disease. In another embodiment, the compounds may be used in the treatment or prophylaxis of neurodegenerative disorders. Also provided herein are methods of allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing a neurodegenerative disease.

8491869, Jul 23, 2013

Mar 23, 2010

12/661777

Umesh B. Gangadharmath - Los Angeles CA, US
Hartmuth C. Kolb - Playa Del Rey CA, US
Peter J. H. Scott - Ypsilanti MI, US
Joseph C. Walsh - Pacific Palisades CA, US
Wei Zhang - Los Angeles CA, US
Anna Katrin Szardenings - Torrance CA, US
Anjana Sinha - San Diego CA, US
Gang Chen - Los Angeles CA, US
Eric Wang - San Diego CA, US
Chul Yu - Los Angeles CA, US
Changhui Liu - Los Angeles CA, US
Daniel Kurt Cashion - Manhattan Beach CA, US
Dhanalakshmi Kasi - Los Angeles CA, US

Eli Lilly and Company - Indianapolis IN

A61K 51/00
A61M 36/14

424 189, 424 111, 424 165, 424 181, 424 185

Imaging agents of formula (I) and methods for detecting neurological disorders comprising administering ti a patient in need compounds of formula (I) capable of binding to tau proteins and β-amyloid peptides are presented herein. The invention also relates to methods of imaging Aβ and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formula (I) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders.

20050070719, Mar 31, 2005

Dec 26, 2002

10/499675

Sergei Belyakov - Baltimore MD, US
Gregory Hamilton - Catonsville MD, US
David Hurst - Santee CA, US
Vincent Kalish - Annapolis MD, US
Weixing Li - Ellicot City MD, US
Eric Wang - San Diego CA, US
Douglas Wilkinson - Baltimore MD, US
Weizheng Xu - Ellicot City MD, US

C07D277/04
C07D233/60

548200000, 548215000, 548530000, 548334100

Novel inhibitors of dipeptidyl peptidase IV (DPP IV), pharmaceutical compositions comprising therapeutically effective amounts of novel inhibitors of DPP IV, and novel methods of treating medical conditions are provided. The novel inhibitors of DPP IV described herein are useful in the treatment of neurological disorders, diabetes, inflammatory disorders such as arthritis, obesity, osteoporosis, and of such other enumerated conditions as can be treated with inhibitors of DPP IV.

20050096360, May 5, 2005

Aug 6, 2004

10/913253

Luisa Salter-Cid - San Diego CA, US
Eric Wang - San Diego CA, US
Keith Cockerill - San Diego CA, US
Matthew Linnik - Solana Beach CA, US
Edward Victoria - San Diego CA, US

A61K031/44
A61K031/15

514357000, 514645000, 514646000, 546332000, 564300000, 564310000

Compositions and methods of using compositions for treatment of inflammatory diseases and immune disorders are provided. Allylhydrazine compounds, hydroxylamine (aminooxy) compounds, and other compounds are disclosed which are inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein 1 (VAP-1). The compounds have therapeutic utility in suppressing inflammation and inflammatory responses, and in treatment of several disorders, including multiple sclerosis.

20060025438, Feb 2, 2006

Feb 25, 2005

11/066786

Luisa Salter-Cid - San Diego CA, US
Eric Wang - San Diego CA, US
Mary MacDonald - San Diego CA, US
Jingjing Zhao - San Diego CA, US

A61K 31/4745
A61K 31/165
A61K 31/47
A61K 31/137

514303000, 514309000, 514620000, 514649000

Compositions and methods are disclosed for inhibiting semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1). The compounds disclosed are amine-containing and amide-containing compounds. The compounds and compositions are useful for treatment of diseases, including inflammation, inflammatory diseases and autoimmune disorders.